Moderna, Inc.

We are mRNA. And mRNA is us.

Every day, we come together to create the blueprints needed to fight and eradicate diseases, and to help people live healthier lives. And the world has witnessed the powerful benefits of our platform technology.

With mRNA technology, we are completely reimagining how medicines are created and delivered. And in the process, we’re launching an entirely new industry, one fueled by deep care for our teams as well as for others.

Through the power of mRNA, we’re giving our people a platform to change medicine—and an opportunity to change the world.

Come with us as we pursue the uncharted reaches of possibility and make your mark on the future of medicine: modernatx.com/careers

200 Technology Square
Cambridge, MA

Tel: 617-714-6500

Visit website

Email Us

Stock Symbol: MRNA
Stock Exchange: USNASDAQ GS

Changing the future of medicine starts with our people. Across Moderna, our colleagues are working to make the impossible possible, and our goal is to support them every step of the way. With a global team and a unique culture, driven by the company’s values and mindsets, Moderna’s mission is to deliver the greatest possible impact to people through mRNA medicines.

Every Role Matters, Enabling Transformative Mission

At Moderna, our changemakers are actively building a better future, one innovation at a time. We recently asked Keke if she could create a six-word story about what being a changemaker meant to her.

Read Keke’s Story

Take your moment with benefits

We know that you will give us your all and we want to make sure that we’re doing the same for you and the people closest to you. We’re on this incredible journey of pushing past the possible together, which is why we provide paramount support for both you and your family.

Learn More

NEWS

Editable vector illustration of a man winning a race. Hi-res jpeg file included.

Approvals

Moderna’s flu shot crosses FDA finish line, bouncing back from regulatory roadblock

The FDA in February slapped Moderna’s vaccine with a refusal-to-file letter—though the agency backtracked a few days later and accepted a revised submission for review. An advisory committee in June unanimously backed mFLUVISA’s approval.

August 6, 2026

2 min read

Tristan Manalac

Pictured: Office building science collage

Career Advice

The top 12 companies hiring in biopharma now

Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.

August 6, 2026

1 min read

Angela Gabriel

Business or economic growth concept with arrow icons on wooden cubes on blue background

Earnings

Moderna maintains 10% growth target despite Phase 3 norovirus miss

Moderna’s norovirus vaccine failed in a Phase 3 trial, but the company still has faith in an ambitious revenue growth target thanks to ex-U.S. vaccine sales and a unanimous FDA adcomm win for mFLUSIVA.

July 31, 2026

4 min read

Gabrielle Masson

Image of Harvard University and pedestrian bridge on Charles River in Cambridge, Massachusetts

Job Trends

6 companies hiring in Cambridge now

Looking for a biopharma job in Cambridge? Roles posted on BioSpace have more than doubled compared to last year.

July 22, 2026

1 min read

Angela Gabriel

Paper plane go to success goal vector business financial concept start up, leadership, creative idea symbol paper art style

Earnings

Q2 earnings arrive as pharma picks up steam, buoyed by dealmaking, policy tailwinds

Biopharma is entering its second-quarter earnings season riding high on a wave of massive deals and venture capital flow, plus a clearing of regulatory and policy overhangs. What can industry watchers expect to hear on the upcoming investor calls?

July 15, 2026

6 min read

Tristan Manalac

A scientist with pill bottles in front of FDA headquarters

FDA

7 FDA decisions to watch for in Q3

Many of the FDA’s decisions this quarter involve applications that have previously been delayed, declined or outright rejected, including one for an mRNA vaccine that became the center of controversy earlier this year.

July 2, 2026

7 min read

Tristan Manalac

Businessmen look at the city from the outskirts.

Pipeline

Moderna looks out to R&D ‘horizons’ as 2028 break-even goal looms

Jefferies expects Moderna to have around seven commercial products in the coming years which, along with a projected 10% revenue growth, could help the company break even in 2028.

June 26, 2026

2 min read

Tristan Manalac

Illustration of hands with thumbs up in a row, radiating positivity and consensus in bright tones on a clean background

Adcomms

Moderna’s mRNA flu shot wins unanimous support at FDA adcomm in rebuke of former leadership

The FDA in February briefly refused to review Moderna’s flu vaccine, citing trial inadequacies, but reversed course a few days later. A verdict is expected by Aug. 5.

June 19, 2026

2 min read

Tristan Manalac

German flags waving in the wind at famous Reichstag building, seat of the German Parliament (Deutscher Bundestag), on a sunny day with blue sky and clouds, central Berlin Mitte district, Germany.

Manufacturing

Moderna mulls deals to rescue German BioNTech plants from closure: report

The takeovers depend on Moderna reaching an agreement with the German government, which risks losing investment from drugmakers over planned healthcare reforms.

June 18, 2026

2 min read

Nick Paul Taylor

JOBS